Japan's Oncolys kicks off cancer trial; Endo trades $130M for an Aspen portfolio;

@FierceBiotech: ICYMI Friday: EuroBiotech Report: $ABBV orders $30M of Galapagos' IPO, Indivior aces schizophrenia trial, $GILD inks Danish deal. More | Follow @FierceBiotech

@JohnCFierce: Hey, $GSK. Hyping a tiny, discovery-stage biotech as a quest for an HIV cure smells of desperation. News | Follow @JohnCFierce

> Japan's Oncolys BioPharma kicked off a Phase I trial of a cancer drug licensed from Astellas Pharma, targeting U.S. patients with solid tumors. More

> Endo ($ENDP) paid $130 million for a stable of drugs from South Africa's Aspen Holdings, expanding its portfolio of proprietary and generic treatments. News

> The FDA approved Bayer's antibiotic moxifloxacin to treat plague. Item

Medical Device News

@FierceMedDev: ICYMI: Philips CEO outlines HealthTech vision as shareholders vote to separate lighting biz. Story | Follow @FierceMedDev

@VarunSaxena2: Concordia running trials to expand use of its laser-activated cancer-fighting drug. FierceDrugDelivery article | Follow @VarunSaxena2

@EmilyWFierce: Novartis grabs Zykadia approval in Europe, setting the stage for PD-L1 showdown. ICYMI from FiercePharma | Follow @EmilyWFierce

> Bayer responds to article critical of its Essure birth control device under FDA investigation. More

> In a move toward an artificial pancreas, Debiotech gains option for Bayer's iSense CGM. Story

> FDA approves Nevro device that eliminates side effect of spinal stimulation. Article

Pharma News

@FiercePharma: Millions more in funding allocated to battle worst avian flu outbreak in U.S. history. FierceAnimalHealth story | Follow @FiercePharma

@CarlyHFierce: Big news! FiercePharmaMarketing will now publish every Monday and Wednesday. More | Follow @CarlyHFierce

> HHS: Actavis could cost the government $6B with Namenda hard switch. Story

> Actavis delivers big Q1 sales boost, thanks to Forest, Allergan buys. Report

Animal Health News

> Millions more in funding allocated to battle worst avian influenza outbreak in U.S. history. Report

> Trupanion reports Q1 loss as marketing spend kicks into high gear. Item

> Mars Petcare forms new alliance to expand use of DNA testing in vet hospitals. More

> Aratana tops estimates as Q1 loss narrows. Article

> Zoetis CEO on cost-cutting push: 'We will be much more focused.' Story

Biotech IT News

> SFW Capital Partners closes $345M analytical tools fund. News

> Pfizer, 23andMe start building 5,000-person lupus database. More

> Agilent bolsters presence in clinical lab software sector with Cartagenia buyout. Report

> Medidata links its cloud platform to Apple's ResearchKit. Story

> Buzz: Apple plans to add 23andMe-style spit kits to ResearchKit studies. Article

Pharma Marketing News

> AdverseEvents: New generation of hep C meds bests older therapies in side-effect reports. More

> Secret doctor letter shows Amarin's true 'free speech' leanings. Article

> That Namenda hard switch Actavis wants? It could cost HHS $6B. Item

> Back-to-'Biogen' shift signals wider industry branding trend. News

> Is there a place for pharma in the emerging EHR market? More

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.